Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2002
Business Overview: NAII formulates, manufactures, and packages encapsulated and compressed tablets and powder blended vitamins and nutritional supplements. The company operates a core private-label contract manufacturing business and a direct-to-consumer (DTC) branded product line. Operations are split between facilities in California, USA, and a wholly-owned subsidiary in Manno, Switzerland (NAIE), which benefits from a tax holiday through fiscal 2005.
Key Financial Metrics
| Metric | Fiscal 2002 | Fiscal 2001 |
|---|---|---|
| Net Sales | $50.0 million | $42.2 million |
| Gross Profit | $11.0 million (22% margin) | $8.2 million (19% margin) |
| Operating Income | $0.3 million | ($2.2 million) loss |
| Net Income | $3.9 million ($0.67/share) | ($4.9 million) loss ($0.85/share) |
| Cash and Cash Equivalents | $0.6 million | $0.5 million |
| Working Capital | $8.7 million | $5.0 million |
| Total Debt | $2.2 million | $4.7 million |
| Capital Expenditures | $1.1 million | $1.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% to $50.0 million, driven by a 47% increase in DTC sales ($8.4 million vs. $5.7 million) and growth in core business sales ($41.6 million vs. $36.5 million).
- Profitability Turnaround: The company returned to profitability with $3.9 million in net income, reversing a $4.9 million loss in the prior year. This was driven by improved gross margins (22% vs. 19%) and the absence of a $1.5 million intangible asset impairment charge recorded in 2001.
- Non-Operating Income: Net income was significantly boosted by $3.4 million in proceeds from the Vitamin Antitrust Litigation settlement and a $0.7 million income tax refund receivable due to new federal tax legislation allowing NOL carrybacks.
- Debt Reduction: Total consolidated debt decreased by $2.5 million to $2.2 million as the company utilized cash flow to pay down obligations.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects operating results to fluctuate. The strategy focuses on geographic diversification via the Swiss facility, expanding DTC product lines, and strengthening customer relationships.
- Liquidity Risk: The company's $2.5 million working capital line of credit expires on October 31, 2002. The current lender has not committed to renew it. The company is negotiating with prospective lenders for a replacement facility. Failure to secure new financing could impair operations.
- Customer Concentration: Two customers (NSA International and Mannatech) accounted for 69% of net sales in fiscal 2002. The loss of either would have a material adverse impact.
- Regulatory Risks: Operations are subject to FDA, FTC, and international regulations. Proposed Good Manufacturing Practices (GMP) for supplements could require product reformulation or increased documentation costs.
- Legal Contingencies: The Vitamin Antitrust Litigation was settled with a final payment of $225,000 received after the fiscal year-end. Other legal actions are ongoing but are not expected to have a material adverse effect.
Investor Verification Checklist
- Credit Facility Renewal: Verify the status of negotiations for the replacement of the $2.5 million line of credit expiring October 31, 2002.
- Customer Retention: Monitor the stability of relationships with NSA International and Mannatech, which represent nearly 70% of revenue.
- Recurring Profitability: Assess whether the $3.9 million net income is sustainable without the one-time $3.4 million antitrust settlement and $0.7 million tax refund.
- Inventory Levels: Review the $1.6 million increase in inventory to ensure it aligns with sales growth and does not indicate obsolescence risks.
- Swiss Operations: Confirm the utilization rates and profitability of the NAIE Swiss facility, which contributed 16% of net sales.